Combination therapies targeting both the K-Ras - JNK axis in CSCs/CSLCs and the bulk tumor component, for instance by conventional chemotherapies, would therefore be a rational and promising approach to treat pancreatic cancers and hopefully other intractable human cancers with Ras mutation. This evidence concerns the gene KRAS and pancreatic neoplasm.